BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

Roche, Lead Pharma form immunology partnershipDutch biotech Lead Pharma Holding B.V. will collaborate with Roche (SIX:ROG; OTCQX:RHHBY) to develop preclinical small molecules against a single, undisclosed target to treat immune-mediated diseases. Lead will receive €10 million...
BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

Setback for Sanofi rare anemia therapySanofi (Euronext:SAN; NASDAQ:SNY) said late Friday that FDA issued a complete response letter to a BLA for anti-C1s mAb sutimlimab to treat hemolysis in adults with cold agglutinin disease, a rare anemia....
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

Cross-border biotech Kira is developing therapeutics for complement-mediated cancer and inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway.  Kira Pharmaceuticals Ltd. was founded in 2017 by Chairman, President...
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics Co. Ltd. (HKEX:2126) fell HK$1.80 to HK$22 after raising HK$2.3 billion ($300 million) in an IPO. Bristol Myers Squibb...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

Fed Bio seeks to eliminate the need for repeated dosing of microbiome therapies for chronic diseases by designing complex bacterial communities that can stably colonize the gut. The biotech, which emerged...
BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

Over the last three and a half years, Novartis Venture Fund has remade its team and narrowed its remit to early-stage opportunities in therapeutics. The fund’s 2020 exits suggest the strategic shift may...
Items per page:
1 - 10 of 2514